Monitoring Anthracycline Cancer Drug-Nucleosome Interaction by NMR Using a Specific Isotope Labeling Approach for Nucleosomal DNA

Publication date

2024-05-02

Authors

van Emmerik, Clara LouiseISNI 0000000506007948
Lobbia, Vincenzo RomanoISNI 0000000492906706
Neefjes, Jacques
Nelissen, Frank H.T.
van Ingen, HugoISNI 0000000388457648

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by

Abstract

Chromatinized DNA is targeted by proteins and small molecules to regulate chromatin function. For example, anthracycline cancer drugs evict nucleosomes in a mechanism that is still poorly understood. We here developed a flexible method for specific isotope labeling of nucleosomal DNA enabling NMR studies of such nucleosome interactions. We describe the synthesis of segmental one-strand 13C-thymidine labeled 601-DNA, the assignment of the methyl signals, and demonstrate its use to observe site-specific binding to the nucleosome by aclarubicin, an anthracycline cancer drug that intercalates into the DNA minor grooves. Our results highlight intrinsic conformational heterogeneity in the 601 DNA sequence and show that aclarubicin binds an exposed AT-rich region near the DNA end. Overall, our data point to a model where the drug invades the nucleosome from the terminal ends inward, eventually resulting in histone eviction and nucleosome disruption.

Keywords

aclarubicin, conformation, DNA, NMR, nucleosome, Biochemistry, Molecular Medicine, Molecular Biology, Organic Chemistry, SDG 3 - Good Health and Well-being

Citation

van Emmerik, C L, Lobbia, V, Neefjes, J, Nelissen, F H T & van Ingen, H 2024, 'Monitoring Anthracycline Cancer Drug-Nucleosome Interaction by NMR Using a Specific Isotope Labeling Approach for Nucleosomal DNA', ChemBioChem, vol. 25, no. 9, e202400111. https://doi.org/10.1002/cbic.202400111